The stock of Xilio Therapeutics Inc (XLO) has gone down by -7.76% for the week, with a -43.38% drop in the past month and a -21.31% drop in the past quarter. The volatility ratio for the week is 12.00%, and the volatility levels for the past 30 days are 15.08% for XLO. The simple moving average for the past 20 days is -10.03% for XLO’s stock, with a -10.49% simple moving average for the past 200 days.
Is It Worth Investing in Xilio Therapeutics Inc (NASDAQ: XLO) Right Now?
Additionally, the 36-month beta value for XLO is -0.26. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for XLO is 14.66M and currently, short sellers hold a 4.74% ratio of that float. The average trading volume of XLO on March 14, 2025 was 4.22M shares.
XLO) stock’s latest price update
Xilio Therapeutics Inc (NASDAQ: XLO)’s stock price has plunge by 4.88relation to previous closing price of 0.80. Nevertheless, the company has seen a -7.76% plunge in its stock price over the last five trading sessions. zacks.com reported 2025-03-11 that Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.64 per share a year ago.
Analysts’ Opinion of XLO
Many brokerage firms have already submitted their reports for XLO stocks, with Chardan Capital Markets repeating the rating for XLO by listing it as a “Buy.” The predicted price for XLO in the upcoming period, according to Chardan Capital Markets is $7 based on the research report published on December 21, 2022 of the previous year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see XLO reach a price target of $36. The rating they have provided for XLO stocks is “Buy” according to the report published on January 10th, 2022.
Raymond James gave a rating of “Outperform” to XLO, setting the target price at $31 in the report published on November 16th of the previous year.
XLO Trading at -9.74% from the 50-Day Moving Average
After a stumble in the market that brought XLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.58% of loss for the given period.
Volatility was left at 15.08%, however, over the last 30 days, the volatility rate increased by 12.00%, as shares sank -34.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.45% lower at present.
During the last 5 trading sessions, XLO fell by -7.59%, which changed the moving average for the period of 200-days by -20.05% in comparison to the 20-day moving average, which settled at $0.9315. In addition, Xilio Therapeutics Inc saw -12.25% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XLO starting from Frankenfield Christopher James, who sale 6,954 shares at the price of $0.98 back on Jan 02 ’25. After this action, Frankenfield Christopher James now owns 12,421 shares of Xilio Therapeutics Inc, valued at $6,841 using the latest closing price.
Brennan Kevin M., the SVP, FINANCE AND ACCOUNTING of Xilio Therapeutics Inc, sale 1,803 shares at $0.98 during a trade that took place back on Jan 02 ’25, which means that Brennan Kevin M. is holding 3,197 shares at $1,774 based on the most recent closing price.
Stock Fundamentals for XLO
Current profitability levels for the company are sitting at:
- -9.4 for the present operating margin
- 0.86 for the gross margin
The net margin for Xilio Therapeutics Inc stands at -9.18. The total capital return value is set at -1.36. Equity return is now at value -170.96, with -82.36 for asset returns.
Based on Xilio Therapeutics Inc (XLO), the company’s capital structure generated 0.32 points at debt to capital in total, while cash flow to debt ratio is standing at -2.26.
Currently, EBITDA for the company is -58.0 million with net debt to EBITDA at 0.81. When we switch over and look at the enterprise to sales, we see a ratio of -1.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.67.
Conclusion
In conclusion, Xilio Therapeutics Inc (XLO) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
